News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Actelion Ltd. Board Nominees Deny Sale is Main Aim
April 4, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - A group of prospective Actelion board members denied speculation they planned to prepare Europe's biggest biotech for sale and said they wanted instead to overhaul it.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Collaboration
Lilly Fronts $100M for CSL’s IL-6 Blocker to Bolster I&I, Cardiovascular Pipeline
February 18, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work?
February 12, 2026
·
4 min read
·
Dan Samorodnitsky
MASH
Madrigal Dives Further Into MASH With up to $4.4B siRNA Deal With Chinese Biotech
February 11, 2026
·
2 min read
·
Tristan Manalac
Artificial intelligence
AI Is Changing Pharma’s Bottom Line Now—But Not Through Splashy Drug Discovery
February 11, 2026
·
8 min read
·
Annalee Armstrong
